You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameErgoloid mesylate
Accession NumberDB01049  (APRD00711, DB01287)
TypeSmall Molecule
GroupsApproved
DescriptionErgoloid mesylate is a dihydrogenated ergot (Claviceps purpurea) derivative alkaloid used as a vasodilator agent. Ergoloid Mesylate is the only vasodilator that has shown mild benefits in the treatment of vascular dementia. Ergoloid Mesylate is a mixture of three different ergotamantriones: dihydroergocornine, dihydroergocristine, and dihydroergocryptine. It has been proposed to be a neuroprotective agent. The mechanism of its therapeutic actions is not clear.
Structure
Thumb
Synonyms
co-dergocrine mesilate
co-dergocrine mesylate
co-dergocrine methanesulfonate
codergocrine mesilate
codergocrine mesylate
codergocrine methanesulfonate
Dihydroergotoxine Mesilate
Dihydroergotoxine Mesylate
dihydroergotoxine methanesulfonate
Dihydroergotoxine Methanesulfonate
dihydroergotoxine methanesulfonates
dihydroergotoxine monomethanesulfonate
dihydrogenated ergot alkaloids
Ergoloid Mesylates
ergoloid methanesulfonate
ergoloid methanesulfonates
hydrogenated ergot alkaloids
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Hydergine Tablets, 1mgtablet1 mgoralSterimax Inc1968-12-31Not applicableCanada
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AlkergotNot Available
GerimalNot Available
HydergineNot Available
Hydergine LCNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNIIX3S33EX3KW
CAS number8067-24-1
WeightAverage: 631.74
Monoisotopic: 631.267584003
Chemical FormulaC30H41N5O8S
InChI KeyInChIKey=FQHMMOGHDWAXDI-WUQHHHCFSA-N
InChI
InChI=1S/C29H37N5O5.CH4O3S/c1-15(2)28(27(37)34-16(3)26(36)33-10-6-9-23(33)29(34,38)39-28)31-25(35)18-11-20-19-7-5-8-21-24(19)17(13-30-21)12-22(20)32(4)14-18;1-5(2,3)4/h5,7-8,13,15-16,18,20,22-23,30,38H,6,9-12,14H2,1-4H3,(H,31,35);1H3,(H,2,3,4)/t16-,18+,20+,22+,23-,28+,29-;/m0./s1
IUPAC Name
(2R,4R,7R)-N-[(1S,2S,4R,7S)-2-hydroxy-7-methyl-5,8-dioxo-4-(propan-2-yl)-3-oxa-6,9-diazatricyclo[7.3.0.0²,⁶]dodecan-4-yl]-6-methyl-6,11-diazatetracyclo[7.6.1.0²,⁷.0¹²,¹⁶]hexadeca-1(16),9,12,14-tetraene-4-carboxamide; methanesulfonic acid
SMILES
CS(O)(=O)=O.[H][C@@]12CCCN1C(=O)[[email protected]](C)N1C(=O)[C@](NC(=O)[[email protected]]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)[C@@]4([H])C3)(O[C@@]21O)C(C)C
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as ergopeptines. These are ergoline derivatives that contain a tripeptide structure attached to the basic ergoline ring in the same location as the amide group of the lysergic acid derivatives.
KingdomOrganic compounds
Super ClassAlkaloids and derivatives
ClassErgoline and derivatives
Sub ClassLysergic acids and derivatives
Direct ParentErgopeptines
Alternative Parents
Substituents
  • Hybrid peptide
  • Ergopeptine
  • Lysergic acid amide
  • Indoloquinoline
  • Benzoquinoline
  • Quinoline-3-carboxamide
  • Pyrroloquinoline
  • N-acyl-alpha amino acid or derivatives
  • Quinoline
  • Piperidinecarboxylic acid
  • Piperidinecarboxamide
  • 3-piperidinecarboxamide
  • Isoindole or derivatives
  • Indole or derivatives
  • Indole
  • Aralkylamine
  • N-alkylpiperazine
  • Benzenoid
  • Piperidine
  • Piperazine
  • Oxazolidinone
  • 1,4-diazinane
  • Heteroaromatic compound
  • Alkanesulfonic acid
  • Tertiary carboxylic acid amide
  • Sulfonyl
  • Sulfonic acid derivative
  • Sulfonic acid
  • Pyrrolidine
  • Pyrrole
  • Methanesulfonate
  • Tertiary aliphatic amine
  • Tertiary amine
  • Secondary carboxylic acid amide
  • Orthocarboxylic acid derivative
  • Lactam
  • Carboxamide group
  • Oxacycle
  • Azacycle
  • Organoheterocyclic compound
  • Carboxylic acid derivative
  • Carboxylic acid amide
  • Alkanolamine
  • Hydrocarbon derivative
  • Organosulfur compound
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Aromatic heteropolycyclic compound
  • Aliphatic acyclic compound
Molecular FrameworkNot Available
External DescriptorsNot Available
Pharmacology
IndicationFor use as an adjunct therapy for patients with dementia.
PharmacodynamicsErgoloid Mesylate may increase cerebral metabolism and blood flow. The role of this medication in the therapy of dementia is controversial. A recent controlled study in patients with Alzheimer's disease found that there was no advantage to the use of ergoloid mesylates compared to placebo, suggesting that ergoloid mesylates may lower scores on some cognitive and behavioral rating scales. Further study is needed to determine the risk-benefit profile of ergoloid mesylates in the treatment of dementia.
Mechanism of actionErgoloid mesylates act centrally, decreasing vascular tone and slowing the heart rate, and acts peripherally to block alpha-receptors. One other possible mechanism is the effect of ergoloid mesylates on neuronal cell metabolism, resulting in improved oxygen uptake and cerebral metabolism, thereby normalizing depressed neurotransmitter levels.
Related Articles
AbsorptionRapidly but incompletely (approximately 25%) absorbed from the gastrointestinal tract. Approximately 50% of the absorbed dose is eliminated by first-pass metabolism.
Volume of distributionNot Available
Protein binding98-99%
Metabolism

Hepatic.

Route of eliminationNot Available
Half life3.5 hours
ClearanceNot Available
ToxicitySymptoms of overdose include dyspnea, hypotension or hypertension, rapid weak pulse, delirium, nausea, vomiting, and bradycardia.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.8284
Blood Brain Barrier-0.9494
Caco-2 permeable-0.6447
P-glycoprotein substrateSubstrate0.6838
P-glycoprotein inhibitor IInhibitor0.6581
P-glycoprotein inhibitor IINon-inhibitor0.8001
Renal organic cation transporterNon-inhibitor0.8838
CYP450 2C9 substrateNon-substrate0.75
CYP450 2D6 substrateNon-substrate0.7966
CYP450 3A4 substrateSubstrate0.6681
CYP450 1A2 substrateNon-inhibitor0.7702
CYP450 2C9 inhibitorNon-inhibitor0.7072
CYP450 2D6 inhibitorNon-inhibitor0.9221
CYP450 2C19 inhibitorNon-inhibitor0.6493
CYP450 3A4 inhibitorNon-inhibitor0.7973
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8464
Ames testNon AMES toxic0.6324
CarcinogenicityNon-carcinogens0.6535
BiodegradationNot ready biodegradable0.9321
Rat acute toxicity2.5438 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8821
hERG inhibition (predictor II)Inhibitor0.5783
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
Tabletoral1 mg
Prices
Unit descriptionCostUnit
Ergoloid mesylates powder87.5USD g
Ergoloid mesylates 1 mg tablet1.3USD tablet
Hydergine 1 mg Tablet1.1USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
logP2.8Not Available
Predicted Properties
PropertyValueSource
logP2.17ChemAxon
pKa (Strongest Acidic)9.71ChemAxon
pKa (Strongest Basic)8.39ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area118.21 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity143.66 m3·mol-1ChemAxon
Polarizability57.99 Å3ChemAxon
Number of Rings7ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesC04AE51C04AE01
AHFS Codes
  • 12:16.00
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (72.9 KB)
Interactions
Drug Interactions
Drug
1,10-PhenanthrolineThe serum concentration of Ergoloid mesylate can be increased when it is combined with 1,10-Phenanthroline.
3,4-DichloroisocoumarinThe serum concentration of Ergoloid mesylate can be increased when it is combined with 3,4-Dichloroisocoumarin.
4-(2-AMINOETHYL)BENZENESULFONYL FLUORIDEThe serum concentration of Ergoloid mesylate can be increased when it is combined with 4-(2-AMINOETHYL)BENZENESULFONYL FLUORIDE.
AcebutololAcebutolol may increase the vasoconstricting activities of Ergoloid mesylate.
AcepromazineThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Acepromazine.
AceprometazineThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Aceprometazine.
AcetophenazineThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Acetophenazine.
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Ergoloid mesylate.
AlmotriptanErgoloid mesylate may increase the vasoconstricting activities of Almotriptan.
AlogliptinThe serum concentration of Ergoloid mesylate can be increased when it is combined with Alogliptin.
Alpha-1-proteinase inhibitorThe serum concentration of Ergoloid mesylate can be increased when it is combined with Alpha-1-proteinase inhibitor.
AlprenololAlprenolol may increase the vasoconstricting activities of Ergoloid mesylate.
AmiodaroneThe metabolism of Ergoloid mesylate can be decreased when combined with Amiodarone.
AmisulprideThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Amisulpride.
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Ergoloid mesylate.
AmoxapineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Ergoloid mesylate.
AmperozideThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Amperozide.
AmprenavirThe serum concentration of Ergoloid mesylate can be increased when it is combined with Amprenavir.
Antithrombin III humanThe serum concentration of Ergoloid mesylate can be increased when it is combined with Antithrombin III human.
ApixabanThe serum concentration of Ergoloid mesylate can be increased when it is combined with Apixaban.
ApomorphineErgoloid mesylate may increase the vasoconstricting activities of Apomorphine.
AprepitantThe serum concentration of Ergoloid mesylate can be increased when it is combined with Aprepitant.
AprotininThe serum concentration of Ergoloid mesylate can be increased when it is combined with Aprotinin.
ArgatrobanThe serum concentration of Ergoloid mesylate can be increased when it is combined with Argatroban.
AripiprazoleThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Aripiprazole.
ArotinololArotinolol may increase the vasoconstricting activities of Ergoloid mesylate.
AsenapineThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Asenapine.
AsunaprevirThe serum concentration of Ergoloid mesylate can be increased when it is combined with Asunaprevir.
AtazanavirThe serum concentration of Ergoloid mesylate can be increased when it is combined with Atazanavir.
AtenololAtenolol may increase the vasoconstricting activities of Ergoloid mesylate.
AtomoxetineThe metabolism of Ergoloid mesylate can be decreased when combined with Atomoxetine.
AzaperoneThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Azaperone.
BatimastatThe serum concentration of Ergoloid mesylate can be increased when it is combined with Batimastat.
BefunololBefunolol may increase the vasoconstricting activities of Ergoloid mesylate.
BenazeprilThe serum concentration of Ergoloid mesylate can be increased when it is combined with Benazepril.
BenzamidineThe serum concentration of Ergoloid mesylate can be increased when it is combined with Benzamidine.
BetaxololBetaxolol may increase the vasoconstricting activities of Ergoloid mesylate.
BevantololBevantolol may increase the vasoconstricting activities of Ergoloid mesylate.
BexaroteneThe serum concentration of Ergoloid mesylate can be decreased when it is combined with Bexarotene.
BifeprunoxThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Bifeprunox.
BisoprololBisoprolol may increase the vasoconstricting activities of Ergoloid mesylate.
BivalirudinThe serum concentration of Ergoloid mesylate can be increased when it is combined with Bivalirudin.
BoceprevirThe serum concentration of Ergoloid mesylate can be increased when it is combined with Boceprevir.
BopindololBopindolol may increase the vasoconstricting activities of Ergoloid mesylate.
BortezomibThe metabolism of Ergoloid mesylate can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Ergoloid mesylate can be decreased when it is combined with Bosentan.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Brexpiprazole.
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Ergoloid mesylate.
BromocriptineErgoloid mesylate may increase the vasoconstricting activities of Bromocriptine.
BufuralolBufuralol may increase the vasoconstricting activities of Ergoloid mesylate.
BupranololBupranolol may increase the vasoconstricting activities of Ergoloid mesylate.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Ergoloid mesylate.
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Ergoloid mesylate.
CabergolineErgoloid mesylate may increase the vasoconstricting activities of Cabergoline.
CandoxatrilThe serum concentration of Ergoloid mesylate can be increased when it is combined with Candoxatril.
CaptoprilThe serum concentration of Ergoloid mesylate can be increased when it is combined with Captopril.
CarbamazepineThe metabolism of Ergoloid mesylate can be increased when combined with Carbamazepine.
CariprazineThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Cariprazine.
CarteololCarteolol may increase the vasoconstricting activities of Ergoloid mesylate.
CarvedilolCarvedilol may increase the vasoconstricting activities of Ergoloid mesylate.
CeliprololCeliprolol may increase the vasoconstricting activities of Ergoloid mesylate.
CeritinibThe serum concentration of Ergoloid mesylate can be increased when it is combined with Ceritinib.
ChlorpromazineThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Chlorpromazine.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Chlorprothixene.
ChymostatinThe serum concentration of Ergoloid mesylate can be increased when it is combined with Chymostatin.
CilastatinThe serum concentration of Ergoloid mesylate can be increased when it is combined with Cilastatin.
CilazaprilThe serum concentration of Ergoloid mesylate can be increased when it is combined with Cilazapril.
CitalopramThe risk or severity of adverse effects can be increased when Citalopram is combined with Ergoloid mesylate.
ClarithromycinThe metabolism of Ergoloid mesylate can be decreased when combined with Clarithromycin.
ClemastineThe metabolism of Ergoloid mesylate can be decreased when combined with Clemastine.
ClomipramineThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Clomipramine.
ClotrimazoleThe metabolism of Ergoloid mesylate can be decreased when combined with Clotrimazole.
ClozapineThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Clozapine.
CobicistatThe metabolism of Ergoloid mesylate can be decreased when combined with Cobicistat.
ConivaptanThe serum concentration of Ergoloid mesylate can be increased when it is combined with Conivaptan.
CrizotinibThe metabolism of Ergoloid mesylate can be decreased when combined with Crizotinib.
CyamemazineThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Cyamemazine.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Ergoloid mesylate.
CyclosporineThe metabolism of Ergoloid mesylate can be decreased when combined with Cyclosporine.
Dabigatran etexilateThe serum concentration of Ergoloid mesylate can be increased when it is combined with Dabigatran etexilate.
DabrafenibThe serum concentration of Ergoloid mesylate can be decreased when it is combined with Dabrafenib.
DapiprazoleThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Dapiprazole.
DapoxetineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Ergoloid mesylate.
DarunavirThe serum concentration of Ergoloid mesylate can be increased when it is combined with Darunavir.
DasatinibThe serum concentration of Ergoloid mesylate can be increased when it is combined with Dasatinib.
DeferasiroxThe serum concentration of Ergoloid mesylate can be decreased when it is combined with Deferasirox.
DelavirdineThe metabolism of Ergoloid mesylate can be decreased when combined with Delavirdine.
DesipramineThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Desipramine.
DesvenlafaxineThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Desvenlafaxine.
DexamethasoneThe serum concentration of Ergoloid mesylate can be decreased when it is combined with Dexamethasone.
DextromethorphanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Ergoloid mesylate.
DihydroergotamineThe metabolism of Ergoloid mesylate can be decreased when combined with Dihydroergotamine.
DihydroergotamineErgoloid mesylate may increase the vasoconstricting activities of Dihydroergotamine.
DiltiazemThe metabolism of Ergoloid mesylate can be decreased when combined with Diltiazem.
DolasetronDolasetron may increase the serotonergic activities of Ergoloid mesylate.
DoxepinThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Doxepin.
DoxycyclineThe metabolism of Ergoloid mesylate can be decreased when combined with Doxycycline.
DronedaroneThe metabolism of Ergoloid mesylate can be decreased when combined with Dronedarone.
DroperidolThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Droperidol.
DuloxetineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Ergoloid mesylate.
EcabetThe serum concentration of Ergoloid mesylate can be increased when it is combined with Ecabet.
EdoxabanThe serum concentration of Ergoloid mesylate can be increased when it is combined with Edoxaban.
EfavirenzThe serum concentration of Ergoloid mesylate can be decreased when it is combined with Efavirenz.
ElafinThe serum concentration of Ergoloid mesylate can be increased when it is combined with Elafin.
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Ergoloid mesylate.
EletriptanErgoloid mesylate may increase the vasoconstricting activities of Eletriptan.
EnalaprilThe serum concentration of Ergoloid mesylate can be increased when it is combined with Enalapril.
EnalaprilatThe serum concentration of Ergoloid mesylate can be increased when it is combined with Enalaprilat.
EnalkirenThe serum concentration of Ergoloid mesylate can be increased when it is combined with Enalkiren.
EnzalutamideThe serum concentration of Ergoloid mesylate can be decreased when it is combined with Enzalutamide.
ErgonovineThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Ergonovine.
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Ergoloid mesylate.
ErgotamineErgoloid mesylate may increase the vasoconstricting activities of Ergotamine.
ErythromycinThe metabolism of Ergoloid mesylate can be decreased when combined with Erythromycin.
EscitalopramThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Escitalopram.
Eslicarbazepine acetateThe serum concentration of Ergoloid mesylate can be decreased when it is combined with Eslicarbazepine acetate.
EsmololEsmolol may increase the vasoconstricting activities of Ergoloid mesylate.
EtravirineThe serum concentration of Ergoloid mesylate can be decreased when it is combined with Etravirine.
FencamfamineThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Fencamfamine.
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Ergoloid mesylate.
FluconazoleThe metabolism of Ergoloid mesylate can be decreased when combined with Fluconazole.
FluoxetineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Ergoloid mesylate.
FlupentixolThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Flupentixol.
FluphenazineThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Fluphenazine.
FluspirileneThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Fluspirilene.
FluvoxamineThe metabolism of Ergoloid mesylate can be decreased when combined with Fluvoxamine.
FluvoxamineThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Fluvoxamine.
FosamprenavirThe serum concentration of Ergoloid mesylate can be increased when it is combined with Fosamprenavir.
FosaprepitantThe serum concentration of Ergoloid mesylate can be increased when it is combined with Fosaprepitant.
FosinoprilThe serum concentration of Ergoloid mesylate can be increased when it is combined with Fosinopril.
FosphenytoinThe metabolism of Ergoloid mesylate can be increased when combined with Fosphenytoin.
FrovatriptanThe risk or severity of adverse effects can be increased when Frovatriptan is combined with Ergoloid mesylate.
FrovatriptanErgoloid mesylate may increase the vasoconstricting activities of Frovatriptan.
Fusidic AcidThe serum concentration of Ergoloid mesylate can be increased when it is combined with Fusidic Acid.
GeldanamycinThe serum concentration of Ergoloid mesylate can be increased when it is combined with Geldanamycin.
GM6001The serum concentration of Ergoloid mesylate can be increased when it is combined with GM6001.
GranisetronGranisetron may increase the serotonergic activities of Ergoloid mesylate.
HaloperidolThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Haloperidol.
HirulogThe serum concentration of Ergoloid mesylate can be increased when it is combined with Hirulog.
IdelalisibThe serum concentration of Ergoloid mesylate can be increased when it is combined with Idelalisib.
IloperidoneThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Iloperidone.
ImatinibThe metabolism of Ergoloid mesylate can be decreased when combined with Imatinib.
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Ergoloid mesylate.
IndenololIndenolol may increase the vasoconstricting activities of Ergoloid mesylate.
IndinavirThe serum concentration of Ergoloid mesylate can be increased when it is combined with Indinavir.
IsavuconazoniumThe metabolism of Ergoloid mesylate can be decreased when combined with Isavuconazonium.
IsocarboxazidThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Isocarboxazid.
IsoflurophateThe serum concentration of Ergoloid mesylate can be increased when it is combined with Isoflurophate.
IsradipineThe metabolism of Ergoloid mesylate can be decreased when combined with Isradipine.
ItraconazoleThe serum concentration of Ergoloid mesylate can be increased when it is combined with Itraconazole.
IvacaftorThe serum concentration of Ergoloid mesylate can be increased when it is combined with Ivacaftor.
IxazomibThe serum concentration of Ergoloid mesylate can be increased when it is combined with Ixazomib.
KetoconazoleThe serum concentration of Ergoloid mesylate can be increased when it is combined with Ketoconazole.
LabetalolLabetalol may increase the vasoconstricting activities of Ergoloid mesylate.
LepirudinThe serum concentration of Ergoloid mesylate can be increased when it is combined with Lepirudin.
LevobunololLevobunolol may increase the vasoconstricting activities of Ergoloid mesylate.
LevomilnacipranThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Levomilnacipran.
LinagliptinThe serum concentration of Ergoloid mesylate can be increased when it is combined with Linagliptin.
LinezolidThe risk or severity of adverse effects can be increased when Linezolid is combined with Ergoloid mesylate.
LisinoprilThe serum concentration of Ergoloid mesylate can be increased when it is combined with Lisinopril.
LisurideErgoloid mesylate may increase the vasoconstricting activities of Lisuride.
LithiumThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Lithium.
LopinavirThe serum concentration of Ergoloid mesylate can be increased when it is combined with Lopinavir.
LorcaserinThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Ergoloid mesylate.
LovastatinThe metabolism of Ergoloid mesylate can be decreased when combined with Lovastatin.
LoxapineThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Loxapine.
Lu AA21004Ergoloid mesylate may increase the vasoconstricting activities of Lu AA21004.
LuliconazoleThe serum concentration of Ergoloid mesylate can be increased when it is combined with Luliconazole.
LurasidoneThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Lurasidone.
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Ergoloid mesylate.
MelperoneThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Melperone.
MesoridazineThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Mesoridazine.
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Ergoloid mesylate.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Methotrimeprazine.
MetipranololMetipranolol may increase the vasoconstricting activities of Ergoloid mesylate.
MetoclopramideThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Metoclopramide.
MetoprololMetoprolol may increase the vasoconstricting activities of Ergoloid mesylate.
MifepristoneThe metabolism of Ergoloid mesylate can be decreased when combined with Mifepristone.
MilnacipranThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Milnacipran.
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Ergoloid mesylate.
MitotaneThe serum concentration of Ergoloid mesylate can be decreased when it is combined with Mitotane.
MoclobemideThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Moclobemide.
ModafinilThe serum concentration of Ergoloid mesylate can be decreased when it is combined with Modafinil.
MoexiprilThe serum concentration of Ergoloid mesylate can be increased when it is combined with Moexipril.
MolindoneThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Molindone.
N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-ProlineThe serum concentration of Ergoloid mesylate can be increased when it is combined with N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-Proline.
NadololNadolol may increase the vasoconstricting activities of Ergoloid mesylate.
NafcillinThe serum concentration of Ergoloid mesylate can be decreased when it is combined with Nafcillin.
NaratriptanThe risk or severity of adverse effects can be increased when Naratriptan is combined with Ergoloid mesylate.
NaratriptanErgoloid mesylate may increase the vasoconstricting activities of Naratriptan.
NCX 4016The serum concentration of Ergoloid mesylate can be increased when it is combined with NCX 4016.
NefazodoneThe metabolism of Ergoloid mesylate can be decreased when combined with Nefazodone.
NefazodoneThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Nefazodone.
NelfinavirThe serum concentration of Ergoloid mesylate can be increased when it is combined with Nelfinavir.
NetupitantThe serum concentration of Ergoloid mesylate can be increased when it is combined with Netupitant.
NevirapineThe metabolism of Ergoloid mesylate can be decreased when combined with Nevirapine.
NilotinibThe metabolism of Ergoloid mesylate can be decreased when combined with Nilotinib.
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Ergoloid mesylate.
NitroglycerinErgoloid mesylate may decrease the vasodilatory activities of Nitroglycerin.
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Ergoloid mesylate.
OlanzapineThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Olanzapine.
OlaparibThe metabolism of Ergoloid mesylate can be decreased when combined with Olaparib.
OmapatrilatThe serum concentration of Ergoloid mesylate can be increased when it is combined with Omapatrilat.
OndansetronThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Ondansetron.
OndansetronOndansetron may increase the serotonergic activities of Ergoloid mesylate.
OsanetantThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Osanetant.
OsimertinibThe serum concentration of Ergoloid mesylate can be increased when it is combined with Osimertinib.
OtamixabanThe serum concentration of Ergoloid mesylate can be increased when it is combined with Otamixaban.
OxprenololOxprenolol may increase the vasoconstricting activities of Ergoloid mesylate.
PalbociclibThe serum concentration of Ergoloid mesylate can be increased when it is combined with Palbociclib.
PaliperidoneThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Paliperidone.
PalonosetronPalonosetron may increase the serotonergic activities of Ergoloid mesylate.
ParoxetineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Ergoloid mesylate.
PenbutololPenbutolol may increase the vasoconstricting activities of Ergoloid mesylate.
PentobarbitalThe metabolism of Ergoloid mesylate can be increased when combined with Pentobarbital.
PergolideErgoloid mesylate may increase the vasoconstricting activities of Pergolide.
PerindoprilThe serum concentration of Ergoloid mesylate can be increased when it is combined with Perindopril.
PerospironeThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Perospirone.
PerphenazineThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Perphenazine.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Ergoloid mesylate.
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Ergoloid mesylate.
PhenobarbitalThe metabolism of Ergoloid mesylate can be increased when combined with Phenobarbital.
PhenytoinThe metabolism of Ergoloid mesylate can be increased when combined with Phenytoin.
PhosphoramidonThe serum concentration of Ergoloid mesylate can be increased when it is combined with Phosphoramidon.
PimozideThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Pimozide.
PindololPindolol may increase the vasoconstricting activities of Ergoloid mesylate.
PipamperoneThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Pipamperone.
PipotiazineThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Pipotiazine.
PosaconazoleThe serum concentration of Ergoloid mesylate can be increased when it is combined with Posaconazole.
PractololPractolol may increase the vasoconstricting activities of Ergoloid mesylate.
PrimidoneThe metabolism of Ergoloid mesylate can be increased when combined with Primidone.
PrinomastatThe serum concentration of Ergoloid mesylate can be increased when it is combined with Prinomastat.
ProcarbazineThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Procarbazine.
ProchlorperazineThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Prochlorperazine.
PromazineThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Promazine.
PromethazineThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Promethazine.
PropericiazineThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Propericiazine.
PropranololPropranolol may increase the vasoconstricting activities of Ergoloid mesylate.
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Ergoloid mesylate.
PRX-00023Ergoloid mesylate may increase the vasoconstricting activities of PRX-00023.
QuetiapineThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Quetiapine.
QuinaprilThe serum concentration of Ergoloid mesylate can be increased when it is combined with Quinapril.
RamiprilThe serum concentration of Ergoloid mesylate can be increased when it is combined with Ramipril.
RanolazineThe metabolism of Ergoloid mesylate can be decreased when combined with Ranolazine.
RasagilineThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Rasagiline.
RemikirenThe serum concentration of Ergoloid mesylate can be increased when it is combined with Remikiren.
RemoxiprideThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Remoxipride.
ReserpineThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Reserpine.
RifabutinThe metabolism of Ergoloid mesylate can be increased when combined with Rifabutin.
RifampicinThe metabolism of Ergoloid mesylate can be increased when combined with Rifampicin.
RifapentineThe metabolism of Ergoloid mesylate can be increased when combined with Rifapentine.
RisperidoneThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Risperidone.
RitonavirThe serum concentration of Ergoloid mesylate can be increased when it is combined with Ritonavir.
RivaroxabanThe serum concentration of Ergoloid mesylate can be increased when it is combined with Rivaroxaban.
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Ergoloid mesylate.
RizatriptanErgoloid mesylate may increase the vasoconstricting activities of Rizatriptan.
RopiniroleErgoloid mesylate may increase the vasoconstricting activities of Ropinirole.
SaquinavirThe serum concentration of Ergoloid mesylate can be increased when it is combined with Saquinavir.
SaxagliptinThe serum concentration of Ergoloid mesylate can be increased when it is combined with Saxagliptin.
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Ergoloid mesylate.
SertindoleThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Sertindole.
SertralineThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Sertraline.
SildenafilThe metabolism of Ergoloid mesylate can be decreased when combined with Sildenafil.
SiltuximabThe serum concentration of Ergoloid mesylate can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Ergoloid mesylate can be increased when it is combined with Simeprevir.
SitagliptinThe serum concentration of Ergoloid mesylate can be increased when it is combined with Sitagliptin.
SotalolSotalol may increase the vasoconstricting activities of Ergoloid mesylate.
SpiraprilThe serum concentration of Ergoloid mesylate can be increased when it is combined with Spirapril.
St. John's WortThe serum concentration of Ergoloid mesylate can be decreased when it is combined with St. John's Wort.
StiripentolThe serum concentration of Ergoloid mesylate can be increased when it is combined with Stiripentol.
SulfisoxazoleThe metabolism of Ergoloid mesylate can be decreased when combined with Sulfisoxazole.
SulpirideThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Sulpiride.
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Ergoloid mesylate.
SumatriptanErgoloid mesylate may increase the vasoconstricting activities of Sumatriptan.
TapentadolThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Tapentadol.
Tedizolid PhosphateTedizolid Phosphate may increase the serotonergic activities of Ergoloid mesylate.
Tedizolid PhosphateThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Tedizolid Phosphate.
TelaprevirThe serum concentration of Ergoloid mesylate can be increased when it is combined with Telaprevir.
TelithromycinThe metabolism of Ergoloid mesylate can be decreased when combined with Telithromycin.
TemocaprilThe serum concentration of Ergoloid mesylate can be increased when it is combined with Temocapril.
ThioproperazineThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Thioproperazine.
ThioridazineThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Thioridazine.
ThiorphanThe serum concentration of Ergoloid mesylate can be increased when it is combined with Thiorphan.
ThiothixeneThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Thiothixene.
TiclopidineThe metabolism of Ergoloid mesylate can be decreased when combined with Ticlopidine.
TimololTimolol may increase the vasoconstricting activities of Ergoloid mesylate.
TipranavirThe serum concentration of Ergoloid mesylate can be increased when it is combined with Tipranavir.
TocilizumabThe serum concentration of Ergoloid mesylate can be decreased when it is combined with Tocilizumab.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Ergoloid mesylate.
TrandolaprilThe serum concentration of Ergoloid mesylate can be increased when it is combined with Trandolapril.
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Ergoloid mesylate.
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Ergoloid mesylate.
TrifluoperazineThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Trifluoperazine.
TriflupromazineThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Triflupromazine.
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Ergoloid mesylate.
UbenimexThe serum concentration of Ergoloid mesylate can be increased when it is combined with Ubenimex.
VenlafaxineThe metabolism of Ergoloid mesylate can be decreased when combined with Venlafaxine.
VenlafaxineThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Venlafaxine.
VerapamilThe metabolism of Ergoloid mesylate can be decreased when combined with Verapamil.
VilazodoneThe risk or severity of adverse effects can be increased when Vilazodone is combined with Ergoloid mesylate.
VilazodoneErgoloid mesylate may increase the vasoconstricting activities of Vilazodone.
VildagliptinThe serum concentration of Ergoloid mesylate can be increased when it is combined with Vildagliptin.
VoriconazoleThe serum concentration of Ergoloid mesylate can be increased when it is combined with Voriconazole.
VortioxetineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Ergoloid mesylate.
VortioxetineErgoloid mesylate may increase the vasoconstricting activities of Vortioxetine.
XimelagatranThe serum concentration of Ergoloid mesylate can be increased when it is combined with Ximelagatran.
ZiprasidoneThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Ziprasidone.
ZiprasidoneThe metabolism of Ergoloid mesylate can be decreased when combined with Ziprasidone.
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Ergoloid mesylate.
ZolmitriptanErgoloid mesylate may increase the vasoconstricting activities of Zolmitriptan.
ZotepineThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Zotepine.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Zuclopenthixol.
Food InteractionsNot Available

Targets

Kind
Protein group
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Thioesterase binding
Specific Function:
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazoline > clonidine > epinephrine > norepinephrine > phenylephrine > dopamine > p-synephrine > p-tyramine > serotonin = p-octopamine. For antagonists, the rank order is yohimbine > phentolamine = mianserine > chlorpromazine = spiperone = prazosin > propanolol > alprenolol = pindolol.
Components:
NameUniProt IDDetails
Alpha-2A adrenergic receptorP08913 Details
Alpha-2B adrenergic receptorP18089 Details
Alpha-2C adrenergic receptorP18825 Details
References
  1. Markstein R: Hydergine: interaction with the neurotransmitter systems in the central nervous system. J Pharmacol. 1985;16 Suppl 3:1-17. [PubMed:2869188 ]
Kind
Protein group
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Protein heterodimerization activity
Specific Function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine(PE)-stimulated ERK signaling in cardiac myocytes.
Components:
NameUniProt IDDetails
Alpha-1A adrenergic receptorP35348 Details
Alpha-1B adrenergic receptorP35368 Details
Alpha-1D adrenergic receptorP25100 Details
References
  1. Markstein R: Hydergine: interaction with the neurotransmitter systems in the central nervous system. J Pharmacol. 1985;16 Suppl 3:1-17. [PubMed:2869188 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates the Na(+)-independent transport of organic anions such as taurocholate, the prostaglandins PGD2, PGE1, PGE2, leukotriene C4, thromboxane B2 and iloprost.
Gene Name:
SLCO2B1
Uniprot ID:
O94956
Molecular Weight:
76709.98 Da
References
  1. Lu WJ, Huang JD, Lai ML: The effects of ergoloid mesylates and ginkgo biloba on the pharmacokinetics of ticlopidine. J Clin Pharmacol. 2006 Jun;46(6):628-34. [PubMed:16707409 ]
Kind
Protein group
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Beta-arrestin family members inhibit signaling via G proteins and mediate activation of alternative signaling pathways. Signaling inhibits adenylate cyclase activity and activates a phosphatidylinositol-calcium second messenger system that regulates the release of Ca(2+) ions from intracellular stores. Plays a role in the regulation of 5-hydroxytryptamine release and in the regulation of dopamine and 5-hydroxytryptamine metabolism. Plays a role in the regulation of dopamine and 5-hydroxytryptamine levels in the brain, and thereby affects neural activity, mood and behavior. Plays a role in the response to anxiogenic stimuli.
Components:
NameUniProt IDDetails
5-hydroxytryptamine receptor 1AP08908 Details
5-hydroxytryptamine receptor 1BP28222 Details
5-hydroxytryptamine receptor 1DP28221 Details
5-hydroxytryptamine receptor 1EP28566 Details
5-hydroxytryptamine receptor 1FP30939 Details
5-hydroxytryptamine receptor 2AP28223 Details
5-hydroxytryptamine receptor 2BP41595 Details
5-hydroxytryptamine receptor 2CP28335 Details
5-hydroxytryptamine receptor 3AP46098 Details
5-hydroxytryptamine receptor 3BO95264 Details
5-hydroxytryptamine receptor 3CQ8WXA8 Details
5-hydroxytryptamine receptor 3DQ70Z44 Details
5-hydroxytryptamine receptor 3EA5X5Y0 Details
5-hydroxytryptamine receptor 4Q13639 Details
5-hydroxytryptamine receptor 6P50406 Details
5-hydroxytryptamine receptor 7P34969 Details
References
  1. Flynn BL, Ranno AE: Pharmacologic management of Alzheimer disease, Part II: Antioxidants, antihypertensives, and ergoloid derivatives. Ann Pharmacother. 1999 Feb;33(2):188-97. [PubMed:10084415 ]
  2. Markstein R: Hydergine: interaction with the neurotransmitter systems in the central nervous system. J Pharmacol. 1985;16 Suppl 3:1-17. [PubMed:2869188 ]
  3. Wadworth AN, Chrisp P: Co-dergocrine mesylate. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in age-related cognitive decline. Drugs Aging. 1992 May-Jun;2(3):153-73. [PubMed:1606351 ]
  4. Korneyev AY, Cincotta AH: Identification of hepatic, non-monoamine, dihydroergocryptine binding sites with significant gender differences. Life Sci. 1996;58(12):241-8. [PubMed:8786706 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonistagonist
General Function:
G-protein coupled amine receptor activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.
Gene Name:
DRD1
Uniprot ID:
P21728
Molecular Weight:
49292.765 Da
References
  1. Flynn BL, Ranno AE: Pharmacologic management of Alzheimer disease, Part II: Antioxidants, antihypertensives, and ergoloid derivatives. Ann Pharmacother. 1999 Feb;33(2):188-97. [PubMed:10084415 ]
  2. Markstein R: Hydergine: interaction with the neurotransmitter systems in the central nervous system. J Pharmacol. 1985;16 Suppl 3:1-17. [PubMed:2869188 ]
  3. Wadworth AN, Chrisp P: Co-dergocrine mesylate. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in age-related cognitive decline. Drugs Aging. 1992 May-Jun;2(3):153-73. [PubMed:1606351 ]
  4. Korneyev AY, Cincotta AH: Identification of hepatic, non-monoamine, dihydroergocryptine binding sites with significant gender differences. Life Sci. 1996;58(12):241-8. [PubMed:8786706 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonistagonist
General Function:
Potassium channel regulator activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name:
DRD2
Uniprot ID:
P14416
Molecular Weight:
50618.91 Da
References
  1. Markstein R: Hydergine: interaction with the neurotransmitter systems in the central nervous system. J Pharmacol. 1985;16 Suppl 3:1-17. [PubMed:2869188 ]
Kind
Protein group
Organism
Human
Pharmacological action
unknown
Actions
agonist
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel (By similarity).
Components:
NameUniProt IDDetails
Gamma-aminobutyric acid receptor subunit alpha-1P14867 Details
Gamma-aminobutyric acid receptor subunit alpha-2P47869 Details
Gamma-aminobutyric acid receptor subunit alpha-3P34903 Details
Gamma-aminobutyric acid receptor subunit alpha-4P48169 Details
Gamma-aminobutyric acid receptor subunit alpha-5P31644 Details
Gamma-aminobutyric acid receptor subunit alpha-6Q16445 Details
Gamma-aminobutyric acid receptor subunit beta-1P18505 Details
Gamma-aminobutyric acid receptor subunit beta-2P47870 Details
Gamma-aminobutyric acid receptor subunit beta-3P28472 Details
Gamma-aminobutyric acid receptor subunit deltaO14764 Details
Gamma-aminobutyric acid receptor subunit epsilonP78334 Details
Gamma-aminobutyric acid receptor subunit gamma-1Q8N1C3 Details
Gamma-aminobutyric acid receptor subunit gamma-2P18507 Details
Gamma-aminobutyric acid receptor subunit gamma-3Q99928 Details
Gamma-aminobutyric acid receptor subunit piO00591 Details
Gamma-aminobutyric acid receptor subunit thetaQ9UN88 Details
References
  1. Tvrdeic A, Pericic D: Effect of ergot alkaloids on 3H-flunitrazepam binding to mouse brain GABAA receptors. Coll Antropol. 2003;27 Suppl 1:175-82. [PubMed:12955907 ]
  2. Tvrdeic A, Pericic D: Dihydrogenated ergot compounds bind with high affinity to GABAA receptor-associated Cl- ionophore. Eur J Pharmacol. 1991 Sep 4;202(1):109-11. [PubMed:1664802 ]
  3. Korneyev AY, Cincotta AH: Identification of hepatic, non-monoamine, dihydroergocryptine binding sites with significant gender differences. Life Sci. 1996;58(12):241-8. [PubMed:8786706 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Althaus M, Retzow A, Castell JV, Gomez-Lechon MJ, Amalou Z, Rose T, Appel K: In vitro identification of the cytochrome P450 isoform responsible for the metabolism of alpha-dihydroergocryptine. Xenobiotica. 2000 Nov;30(11):1033-45. [PubMed:11197065 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23